Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HitGenSHSE:688222 +3.04%90 Interest Coverage is 18.47 as of Mar. 2026, which is 57% above its 10-year median of 11.75. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.07 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 376 Biotechnology companies, HitGen ranks worse than 73.4% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. HitGen's
Operating Income
for the
three
months ended in Mar. 2026 was ¥49.7 Mil. HitGen's Interest Expense for the
three
months ended in Mar. 2026 was ¥-2.7 Mil.
HitGen's interest coverage for the quarter that ended in Mar. 2026 was 18.47.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for HitGen's Interest Coverage or its related term are showing as below:
SHSE:688222'
s Interest Coverage Range Over the Past 10 Years
Min: 2.63 Med: 11.75 Max: 216.46
Current: 13.67
SHSE:688222's Interest Coverage is ranked worse than 73.4% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs SHSE:688222: 13.67
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
HitGen Interest Coverage Related Terms
HitGen Interest Coverage Historical Data
* Premium members only.
The historical data trend for HitGen's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SHSE:688222 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, HitGen's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HitGen Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HitGen's Interest Coverage distribution charts can be found below:
* The bar in red indicates where HitGen's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HitGen (SHSE:688222) has a Interest Coverage of 18.47 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HitGen and its competitors. This is 57% above median its historical median of 11.75. Over the past decade, HitGen's Interest Coverage has ranged from 2.63 to 216.46. According to the industry distribution chart, HitGen ranks #276 out of 376 companies in the Biotechnology industry, placing it in the top 73.4%.
Is HitGen's Interest Coverage too high?
HitGen's current Interest Coverage of 18.47 is 57% above median its 10-year median of 11.75. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 216.46. The Biotechnology industry median Interest Coverage is 104.03. HitGen's value of 18.47 is 82.2% below this industry median. Based on the distribution chart, HitGen ranks #276 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HitGen has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HitGen's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HitGen ranks #276 out of 376 companies for Interest Coverage. This places HitGen in the lower half of its industry. The industry median Interest Coverage is 104.03. HitGen's value of 18.47 is 82.2% below this benchmark. Historically, HitGen's own Interest Coverage has ranged from 2.63 to 216.46 over the past decade. While the company's 10-year median is 11.75 vs. the industry median of 104.03, HitGen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HitGen's current Interest Coverage of 18.47 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HitGen and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HitGen's current Interest Coverage is 18.47, which is 57% above median its own 10-year median of 11.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.07, compared to a current price of ¥29.16 — trading 11.9% above its estimated fair value. The current Interest Coverage is 18.47, which is 57% above median its 10-year median of 11.75 and 82.2% below the Biotechnology industry median of 104.03. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For HitGen (SHSE:688222), the current Interest Coverage is 18.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HitGen (SHSE:688222) Overvalued in 2026?
Based on GuruFocus' analysis, HitGen stock appears to be overvalued.
The current stock price of ¥29.16 is trading 11.9% above its estimated GF Value™ of ¥26.07.
GuruFocus considers HitGen to be Modestly Overvalued.
Key valuation signals for SHSE:688222:
Interest Coverage: 18.47 (57% above median its 10-year median of 11.75)
GF Value™: ¥26.07 vs. price of ¥29.16 (11.9% above fair value)
Industry Position: 82.2% below the Biotechnology median (#276 of 376)
No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score
Get the complete analysis for SHSE:688222
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688222 has been successfully added to your 
